All articles by Verdict Staff
Verdict Staff
Lyxor Asset Management restructures business to drive growth
Societe Generale Group-owned French firm Lyxor Asset Management has restructured its business into three strategic lines in a bid to boost growth over the next three years.
Barclays names new director GI&S Trust division in Jersey
Barclays has named Norson Harris as new director for its Global Investments and Solutions Trust (GI&S Trust) division in Jersey.
Ashcourt Rowan H1 revenue surges 31%
British wealth manager Ashcourt Rowan has posted revenue of £19.9m for the six months ended 30 September, up 31% from £15.2m during the same period year ago.
Jersey regulator issues warning to avoid business with fake Channel Offshore Bank
The Jersey Financial Services Commission has issued warning to investors and consumers to avoid business with Channel Offshore Bank (COB), which claims to operate in the Channel Islands.
Schroders set to launch new multi-asset income fund in UK next month
Schroders is planning to launch a new global multi-asset fund for investors in the UK on 19 December 2014.
SCORPEO opens new US office in Boston
SCORPEO, the multi asset class service provider, has opened a new US office in Boston and appointed Jack McNally as managing director for the Boston office.
Cofunds partners with Square Mile Investment for fund research
Cofunds, a general investment platform in the UK, has partnered with Square Mile Investment Consulting and Research for fund research.
Cypress Wealth Advisors names Justin Renaudin as principal
San Francisco-based Cypress Wealth Advisors has named Justin Renaudin as new principal of the firm.
FCA review reveals inadequate monitoring of in-house investment products
The Financial Conduct Authority (FCA) has set out good and bad practices for wealth managers and private banking firms with their own in-house investment products, following its review into the sector.
Neil Woodford to roll out new fund for small biotech firms
UK-based investment manager Neil Woodford is set to launch a new fund in 2015 targeted at small biotechnology companies which are not listed on the stock exchange.